Pliant Therapeutics Inc (PLRX)

$11.21 -0.39 (-3.36%)
Market Cap 705.91M
Revenue (ttm) 1.58M
Net Income (ttm) -161.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,211.39%
Debt to Equity Ratio 0.09
Volume 672,600
Avg Vol 528,400
Day's Range N/A - N/A
Shares Out 60.85M
Stochastic %K 10%
Beta 1.05
Analysts Strong Sell
Price Target $40.55

Latest News on PLRX

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

Nov 18, 2024, 6:00 PM EST - 2 months ago

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Oct 1, 2024, 4:35 PM EDT - 3 months ago

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 30, 2024, 4:45 PM EDT - 3 months ago

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Pliant Therapeutics to Participate in Upcoming Investor Events

Aug 28, 2024, 8:00 AM EDT - 5 months ago

Pliant Therapeutics to Participate in Upcoming Investor Events

Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

Aug 26, 2024, 9:10 AM EDT - 5 months ago

Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 6, 2024, 4:03 PM EDT - 5 months ago

Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

Jun 13, 2024, 4:05 PM EDT - 7 months ago

Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

Jun 6, 2024, 8:00 AM EDT - 8 months ago

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

May 21, 2024, 6:50 PM EDT - 8 months ago

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

May 14, 2024, 7:30 AM EDT - 8 months ago

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™

May 7, 2024, 8:00 AM EDT - 9 months ago

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 9 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Mar 27, 2024, 10:23 AM EDT - 10 months ago

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Mar 12, 2024, 7:30 AM EDT - 11 months ago

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Feb 27, 2024, 4:03 PM EST - 11 months ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Pliant Therapeutics to Participate in Upcoming Investor Conferences

Feb 26, 2024, 8:00 AM EST - 11 months ago

Pliant Therapeutics to Participate in Upcoming Investor Conferences

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Feb 4, 2024, 3:29 PM EST - 1 year ago

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 1 year ago

Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

Nov 13, 2023, 4:30 PM EST - 1 year ago

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1

Nov 6, 2023, 8:00 AM EST - 1 year ago

Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer

Oct 31, 2023, 4:03 PM EDT - 1 year ago

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

Oct 16, 2023, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics' Multi-Pronged Fibrosis Play

Sep 26, 2023, 2:31 PM EDT - 1 year ago

Pliant Therapeutics' Multi-Pronged Fibrosis Play

Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial

Sep 26, 2023, 8:09 AM EDT - 1 year ago

Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Sep 26, 2023, 7:30 AM EDT - 1 year ago

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

Sep 25, 2023, 4:05 PM EDT - 1 year ago

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

Sep 15, 2023, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

Sep 11, 2023, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

Aug 28, 2023, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled

Aug 11, 2023, 12:19 PM EDT - 1 year ago

Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 9, 2023, 4:03 PM EDT - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

Aug 9, 2023, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

Jun 23, 2023, 7:30 AM EDT - 1 year ago

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

Pliant Therapeutics: Trading In Oversold Territory, Buying The Dip

May 23, 2023, 8:35 AM EDT - 1 year ago

Pliant Therapeutics: Trading In Oversold Territory, Buying The Dip

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 9, 2023, 4:02 PM EDT - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Apr 30, 2023, 2:10 PM EDT - 1 year ago

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market

Apr 15, 2023, 7:55 AM EDT - 1 year ago

Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

Apr 12, 2023, 8:01 AM EDT - 1 year ago

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

Mar 27, 2023, 8:01 AM EDT - 1 year ago

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

Pliant Therapeutics: Latest Financials Support Stable Investment In Future Growth

Mar 15, 2023, 10:53 AM EDT - 2 years ago

Pliant Therapeutics: Latest Financials Support Stable Investment In Future Growth

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

Mar 13, 2023, 8:01 AM EDT - 2 years ago

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

Mar 9, 2023, 4:05 PM EST - 2 years ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

Mar 8, 2023, 4:01 PM EST - 2 years ago

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

Pliant Therapeutics' Bexotegrast Shows Promise For Idiopathic Pulmonary Fibrosis

Mar 3, 2023, 10:48 AM EST - 2 years ago

Pliant Therapeutics' Bexotegrast Shows Promise For Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Feb 2, 2023, 8:02 AM EST - 2 years ago

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jan 27, 2023, 4:03 PM EST - 2 years ago

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

Jan 25, 2023, 8:01 AM EST - 2 years ago

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

Jan 24, 2023, 9:19 PM EST - 2 years ago

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering